Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Haematology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.12299PMID 23530930PMCID PMC4068703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

  2012cited by this paper
• Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

  2012cited by this paper
• FLT3/ITD AML and the law of unintended consequences.

  2011cited by this paper
• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

  2011cited by this paper
• FLT3 inhibitors in the treatment of acute myeloid leukemia

  2011cited by this paper
• Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.

  2011cited by this paper
• Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

  2010influential reference
• Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

  2010cited by this paper
• Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

  2010influential reference
• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  2009cited by this paper
• AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

  2009cited by this paper
• Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

  2009cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008cited by this paper
• Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

  2008cited by this paper
• Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.

  2006cited by this paper
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

  2005cited by this paper
• Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.

  2004cited by this paper
• In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

  2004cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

  2004cited by this paper
• The role of FLT3 in haematopoietic malignancies

  2003cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

  2002cited by this paper
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002cited by this paper
• Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

  2001cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• Prognostic Implication of FLT 3 and N-RAS Gene Mutations in Acute Myeloid Leukemia

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper

• Tyrosine kinase inhibitor maintenance therapy after stem cell transplantation for FLT3‐mutated acute myeloid leukemia

  2025cites this paper
• Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

  2023cites this paper
• A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules

  2021cites this paper
• Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia

  2021cites this paper
• Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.

  2020cites this paper
• Overcoming the Protective Effect of the Bone Marrow Microenvironment by Dual FLT3 and BET Inhibition in FLT3-ITD Acute Myeloid Leukemia

  2019cites this paper
• Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Therapy-Related Myeloid Neoplasms, and Acute Myeloid Leukemia, Not Otherwise Specified

  2018cites this paper
• Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients

  2018cites this paper
• Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

  2018cites this paper
• FLT3 inhibition in acute myeloid leukaemia.

  2017cites this paper
• Acute myeloid leukemia—Major progress over four decades and glimpses into the future

  2016cites this paper
• Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

  2016cites this paper
• Treatment and prognostic assessment of acute myeloid leukemia

  2016cites this paper
• Approach to patients with primary refractory acute myeloid leukemia

  2015cites this paper
• Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

  2015cites this paper
• Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

  2015cites this paper
• FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

  2015cites this paper
• Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

  2014cites this paper
• Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

  2014cites this paper
• Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial

  2014cites this paper
• Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia

  2014cites this paper
• Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

  2013cites this paper
• Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.

  2013cites this paper